At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 80 enrolled
Drug / intervention
BI 1026706 Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1026706 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, and Investigation of Relative Bioavailability of BI 1026706 (Open-label, Randomised, Four-way Cross-over)
In Brief
A Phase 1 clinical trial evaluating BI 1026706 Placebo and BI 1026706 for Healthy. Completed, enrolled 80 participants across 1 site.
Detailed Summary
To investigate the safety, tolerability, pharmacokinetics and the relative bioavailability of BI 1026706
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartJan 2013
Primary CompletionSep 2013
TodayJul 2026
First PostedJan 8, 2013
Enrollment StartJan 8, 2013
Primary CompletionSep 4, 2013
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 13.5 years ago
Interventions
BI 1026706 Placebodrug
Placebo to BI 1026706
BI 1026706drug
different dose formulations